Vol 85, No 6 (2014)
ARTICLES
VEGF – targeted therapy for the treatment of cervical cancer – literature review
Magdalena Salomon-Pierzyńska, Beata Rembielak-Stawecka, Bogdan Michalski, Aleksander Perzyński, Violetta Skrzypulec-Plinta
DOI: 10.17772/gp/1754
·
Ginekol Pol 2014;85(6).
Vol 85, No 6 (2014)
ARTICLES
Abstract
Cervical cancer is the third most common malignancy and the fourth leading cause of cancer-related death among women worldwide. Advances in the knowledge about molecular mechanisms of carcinogenesis have created opportunities for greater use of targeted therapies in contemporary oncology. In view of the unsatisfactory results of advanced cervical cancer treatment and a well-documented role of the vascular endothelial growth factor (VEGF) family members in pathogenesis and progression of cervical cancer, the use of VEGF-targeted therapy in the treatment of cervical cancer offers interesting possibilities. The efficacy of bevacizumab, a monoclonal antibody neutralizing VEGF-A in the treatment of cervical cancer, was first suggested in 2006 by a small retrospective analysis and confirmed in several Phase II clinical trials. Preliminary results of the randomized phase III studies presented at this year’s ASCO (American Society of Clinical Oncology) conference shed new light on the role of VEGF-targeted therapy in the treatment of cervical cancer, as they demonstrated that addition of bevacizumab to chemotherapy is associated with significantly improved overall survival in the group of patients with persistent, recurrent or metastatic cervical cancer.
Abstract
Cervical cancer is the third most common malignancy and the fourth leading cause of cancer-related death among women worldwide. Advances in the knowledge about molecular mechanisms of carcinogenesis have created opportunities for greater use of targeted therapies in contemporary oncology. In view of the unsatisfactory results of advanced cervical cancer treatment and a well-documented role of the vascular endothelial growth factor (VEGF) family members in pathogenesis and progression of cervical cancer, the use of VEGF-targeted therapy in the treatment of cervical cancer offers interesting possibilities. The efficacy of bevacizumab, a monoclonal antibody neutralizing VEGF-A in the treatment of cervical cancer, was first suggested in 2006 by a small retrospective analysis and confirmed in several Phase II clinical trials. Preliminary results of the randomized phase III studies presented at this year’s ASCO (American Society of Clinical Oncology) conference shed new light on the role of VEGF-targeted therapy in the treatment of cervical cancer, as they demonstrated that addition of bevacizumab to chemotherapy is associated with significantly improved overall survival in the group of patients with persistent, recurrent or metastatic cervical cancer.
Keywords
bevacizumab, cervical cancer, molecular targeted therap, VEGF
Title
VEGF – targeted therapy for the treatment of cervical cancer – literature review
Journal
Ginekologia Polska
Issue
Vol 85, No 6 (2014)
Page views
1355
Article views/downloads
1491
DOI
10.17772/gp/1754
Bibliographic record
Ginekol Pol 2014;85(6).
Keywords
bevacizumab
cervical cancer
molecular targeted therap
VEGF
Authors
Magdalena Salomon-Pierzyńska
Beata Rembielak-Stawecka
Bogdan Michalski
Aleksander Perzyński
Violetta Skrzypulec-Plinta
About this article